**Supplementary Table 3.** Demographic and treatment descriptive characteristics of POSEIDON patients, stratified by group and study’s center.

|  |  |  |
| --- | --- | --- |
|  |  | **POSEIDON Groups** |
|  | **Total****n=5,639** | **Group 1****n=2,493** | **Group 2****n=2,038** | **Group3** **n=294** | **Group 4****n=814** |
| **Age (years)***Study Center 1**Study Center 2**Study Center 3* | 37 [34-40]32 [29-36]35 [32-39] | 31 [28-33]32 [30-34]30 [27-32]31 [29-33] | 38 [36-40]38 [35-45]37 [36-40]38 [36-40] | 32 [30-33]33 [31-33]31 [28-32]32 [30-33] | 39 [37-42]40 [37-43]39 [37-41]39 [37-42] |
| **BMI (kg/m2)***Study Center 1**Study Center 2**Study Center 3* | 23.7 [21.8-26.4]24.8 [22.0-28.4]20.8 [19.6-22.5] | 21.9 [20.0-24.8]22.8 [21.3-26.1]24.6 [22.0-28.3)20.5 [19.3-22.1] | 22.2 [20.4-24.9]23.9 [22.0-26.1]25.4 [22.7-28.9]21.2 [20.0-22.8] | 20.8 [19.5-23.0]23.2 [20.7-25.0]23.0 [21.2-26.5]20.3 [19.1-21.9] | 21.8 [20.2-23.8]24.4 [22.2-27.8]24.5 [19.0-37.8]21.2 [20.0-22.8] |
| **Infertility duration (months)***Study Center 1**Study Center 2**Study Center 3* | 48 [24-96]48 [24-84]48 [24-84] | 48 [24-172]42 [24-61]48 [25-72]48 [24-72] | 60 [24-96]48 [24-120]48 [24-108]60 [24-108] | 48 [24-72]42 [36-84]36 [18-72]48 [24-84] | 60 [24-108]52 [32-120]48 [24-116]60 [24-108] |
| **Primary indication ART (Male factor)***Study Center 1**Study Center 2**Study Center 3* | 91/592 (15.4)540/1,783 (30.3)660/3,264 (20.2) | 825/2,493 (33.1)23/126 (18.2)384/1,051 (36.5)418/1,316 (31.7) | 394/2,038 (19.3)56/292 (19.2)146/532 (27.5)192/1,214 (15.8) | 26/294 (8.8)2/40 (0.5)4/51 (7.8)20/203 (9.8) | 51/814 (6.2)10/134 (7.5)11/149 (7.4)30/531 (5.6) |
| **Primary indication ART (Female factor)***Study Center 1**Study Center 2**Study Center 3* | 242/592 (40.9)621/1,783 (34.8)2,336/3,264 (71.6) | 1,026/2,493 (41.1)30/126 (23.8)260/1,051 (24.7)736/1,316 (56.0) | 1,286/2,038 (63.1)167/292 (57.2)188/532 (35.3)931/1,214 (76.7) | 251/294 (85.4)35/40 (82.0)38/51 (74.5)178/203 (87.8) | 711/814 (87.3)95/134 (70.9)125/149 (83.9)491/531 (92.5) |
| **Primary indication ART****(Unexplained infertility)***Study Center 1**Study Center 2**Study Center 3* | 151/592 (25.5)622/1,783 (34.9)268/3,264 (8.2) | 642/2,493 (25.7)73/126 (58.0)407/1,051 (38.8)162/1,316 (12.3) | 358/2,038 (17.6)69/292 (23.6)198/532 (17.2)91/1,214 (7.5) | 22/294 (7.5)7/40 (17.5)10/51 (19.7)5/203 (2.4) | 52/814 (6.4)29/134 (21.6)13/149 (8.7)10/531 (1.9) |
| **AFC (n)***Study Center 1**Study Center 2**Study Center 3* | 6 [4-8]11 [8-15]7 [5-11] | 11 [8-15]7 [6-10]12 [9-17]10 [7-14] | 8 [6-10]7 [6-8]10 [8-12]8 [6-10] | 3 [3-4]3 [2-4]3 [3-4]3 [2-4] | 3 [2-4]3 [2-4]3 [2-4]3 [2-4] |
| **AMH (ng/mL)***Study Center 1**Study Center 2**Study Center 3* | 0.9 [0.4-1.8]1.1 [0.6-2.0]1.7 [1.0-3.3] | 2.5 [1.3-4.4]1.5 [0.8-2.3]1.9 [0.9-3.0]2.7 [1.4-4.6] | 1.6 [1.0-2.8]1.2 [0.6-2.0]1.2 [0.7-1.6]1.8 [1.1-3.1] | 0.7 [0.3-1.2]0.4 [0.1-0.7]0.4 [0.1-0.8]0.9 [0.5-1.4] | 0.7 [0.3-1.2]0.3 [0.1-0.7]0.3 [0.2-0.6]0.8 [0.4-1.2] |
| **Duration of stimulation (days)***Study Center 1**Study Center 2**Study Center 3* | 10 [10-10]9 [8-11]9 [8-10] | 9 [8-10]10 [10-10]9 [8-10]9 [8-10] | 9 [8-10]10 [10-10]9 [8-11]9 [8-10] | 9 [8-11]10 [10-10]10 [8-11]9 [8-11] | 9 [8-11]10 [10-10]10 [8-12]9 [8-11] |
| **GnRH analogue (Antagonist)***Study Center 1**Study Center 2**Study Center 3* | 562/592 (94.9)677/1,783 (37.9)3,264/3,264 (100.0) | 1,893/2,493 (75.9)120/126 (95.0)457/1,051 (43.5)1,316/1,316 (100.0) | 1,631/2,038 (80.0)273/292 (93.5)144/532 (27.0)1,214/1,214 (100.0) | 256/294 (87.1)38/40 (95.0)15/51 (29.4)203/203 (100.0) | 731/814 (89.8)131/134 (97.8)69/149 (46.3)531/531 (100.0) |
| **GnRH analogue (Agonist)***Study Center 1**Study Center 2**Study Center 3* | 30/592 (5.1) 1,106/1,783 (62.1)0/3,264 (0.0) | 600/2,493 (24.1)6/126 (5.0)594/1,051 (56.5)0/1,316 (0.0) | 407/2,038 (20.0)19/292 (6.5)388/532 (73.0)0/1214 (0.0) | 38/294 (12.9)2/40 (5.0)36/51 (70.6)0/203 (0.0) | 82/814 (10.1)3/134 (2.2)79/149 (53.7)0/531 (0.0) |
| **Total gonadotropin dose (IU)***Study Center 1**Study Center 2**Study Center 3* | 3,000 [2,250-3,300]2,025 [1,500-2,925]3,000 [2,400-3,450] | 2,400 [1,725-3,000]2,625 [2,025-3,000]1,800 [1,350-2,400]2,775 [2,250-3,450] | 2,902 [2,400-3,450]3,000 [2,250-4,000]2,598 [1,800-3,300]3,000 [2,550-3,450] | 3,000 [2,700-3,937]3,000 [2,362-3,893]3,300 [2,400-4,500]3,075 [2,700-3,900] | 3,075 [2,550-4,050]3,000 (2,250-3,300]4,050 [2,400-4,950]3,075 [2,550-3,900] |
| **Gonadotropin (HMG)***Study Center 1**Study Center 2**Study Center 3* | 1/592 (0.1)142/1,783 (8.0)31/3,264 (0.9) | 88/2,493 (3.5)0/126 (0.0)82/1,051 (7.8)6/1,316 (0.4) | 48/2,038 (2.3)0/292 (0.0)37/532 (7.0)11/1,214 (0.9) | 11/294 (3.7)0/40 (0.0)5/51 (9.8)6/203 (3.0) | 28/814 (3.4)0 (0.0)20/149 (13.5)8/531 (1.5) |
| **Gonadotropin (rFSH)***Study Center 1**Study Center 2**Study Center 3* | 297/592 (50.2)784/1,783 (44.0)526/3,264 (16.1) | 920/2,493 (36.9)102/126 (81.0)595/1,051 (56.6)223/1,316 (16.9) | 491/2,038 (24.1)123/292 (42.1)149/532 (28.0)219/1,214 (18.0) | 60/294 (20.4)30/40 (75.0)8/51 (15.7)22/203 (10.8) | 111/814 (13.6)42/134 (31.3)7/149 (4.7)62/531 (11.7) |
| **Gonadotropin (rFSH+HMG)***Study Center 1**Study Center 2**Study Center 3* | 0/592 (0.0)713/1783 (40.0)2573/3264 (78.9) | 1368/2,493 (54.9)0/126 (0.0)316/1,051 (30.1)1,052/1,316 (80.0) | 1205/2,038 (59.1)1/292 (0.3)282/532 (53.0)922/1,214 (76.0) | 196/294 (66.7)0/40 (0.0)28/51 (54.9)168/203 (82.7) | 544/814 (66.8)0 (0.0)113/149 (75.8)431/531 (81.2) |
| **Gonadotropin (rFSH+rLH)***Study Center 1**Study Center 2**Study Center 3* | 294/592 (49.7)144/1,783 (8.0)134/3,264 (4.1) | 117/2,493 (4.7)24/126 (19.0)58/1,051 (5.5)35/1,316 (2.7) | 294/2,038 (14.4)168/292 (57.6)64/532 (12.0)62/1,214 (5.1) | 27/294 (9.2)10/40 (25.0)10/51 (19.6)7/203 (3.5) | 131/814 (16.2)92/134 (68.7)9/149 6.0)30/531 (5.6) |
| **Trigger type (hCG)** *Study Center 1**Study Center 2**Study Center 3* | 198/592 (33.4)1,734/1,783 (97.2)3,223/3,264 (98.7) | 2,394/2,493 (96.0)91/126 (72.0)1,020/1,051 (97.0)1,283/1,316 (97.5) | 1,920/2,038 (94.2)194/292 (66.4)520/532 (97.7)1,206/1,214 (99.3) | 281/294 (95.6)27/40 (67.5)51/51 (100.0)203/203 (100.0) | 616/814 (75.7)82/134 (61.2)3/149 (3.0)531/531 (100.0) |
| **Trigger type (GnRH agonist)***Study Center 1**Study Center 2**Study Center 3* | 394/592 (66.6)49/1,783 (2.8)41/3,264 (1.2) | 99/2,493 (4.0)35/126 (28.0)31/1,051 (3.0)33/1,316 (2.5) | 118/2,038 (5.8)98/292 (33.6)12/532 (2.3)8/1214 (0.7) | 13/294 (4.4)13/40 (32.5)0 (0.0)0.(0.0) | 198/814 (24.3)52/134 (38.8)146/149 (97.0)0/531 (0.0) |
| **Number of oocytes retrieved***Study Center 1**Study Center 2**Study Center 3* | 5 [3-7]7 [5-8]6 [4-8] | 7 [5-8]7 [5-8]7 [5-8]7 [5-8] | 6 [4-8]5 [3-7]7 [5-8]6 [4-8] | 3 [2-5]3 [1-4]3 [1-5]3 [2-5] | 3 [1-4]2 [1-4]3 [1-4]3 [2-5] |

Values are median and 25%-75% interquartile range

Study Center 1: ANDROFERT (Brazil); Study Center 2: Anatolia IVF (Turkey); Study Center 3: My Duc Hospital (Vietnam)